Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Link

Showing results (801-810 of 819) with videos related to

Pageof 82
Sort By:
Journal of Neurosurgery|November 10, 2023
Immunohistochemical markers predicting recurrence following resection and radiotherapy in chordoma patients: insights from a multicenter study [RETRACTED]Antonio Bon Nieves, Abdul Karim Ghaith, Victor Gabriel El-Hajj, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Journal of Neurosurgery|January 22, 2026
Prognostic factors for 90-day survival after stereotactic radiosurgery for brain metastasis patientsAli Gharibi Loron, William D Chow, Andrew D Pumford, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Human Gene Therapy|February 11, 1998
Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103C J Link, R K Burt, A E Traynor, et al.
The Journal of Clinical Investigation|April 2, 2013
Discovering naturally processed antigenic determinants that confer protective T cell immunityPavlo Gilchuk, Charles T Spencer, Stephanie B Conant, et al.
Data in Brief|February 7, 2023
Characterization data of reference materials used for phase II of the priority program DFG SPP 2005 "Opus Fluidum Futurum - Rheology of reactive, multiscale, multiphase construction materials"U Pott, C Crasselt, N Fobbe, et al.
Acta Neurochirurgica|July 31, 2020
Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base sectionDaniele Starnoni, Lorenzo Giammattei, Giulia Cossu, et al.
Neuro-Oncology Advances|October 16, 2023
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patientsM J Webb, Bryan J Neth, Lauren M Webb, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|January 25, 2021
Working Toward Consensus on Sporadic Vestibular Schwannoma Care: A Modified Delphi StudyMatthew L Carlson, Michael J Link, Colin L W Driscoll, et al.
Pageof 82

Showing results (801-810 of 819) with videos related to

Sort By:
Pageof 82
Journal of Neurosurgery|November 10, 2023
Immunohistochemical markers predicting recurrence following resection and radiotherapy in chordoma patients: insights from a multicenter study [RETRACTED]Antonio Bon Nieves, Abdul Karim Ghaith, Victor Gabriel El-Hajj, et al.
Journal for Immunotherapy of Cancer|June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaYousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Journal of Neurosurgery|January 22, 2026
Prognostic factors for 90-day survival after stereotactic radiosurgery for brain metastasis patientsAli Gharibi Loron, William D Chow, Andrew D Pumford, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Human Gene Therapy|February 11, 1998
Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103C J Link, R K Burt, A E Traynor, et al.
The Journal of Clinical Investigation|April 2, 2013
Discovering naturally processed antigenic determinants that confer protective T cell immunityPavlo Gilchuk, Charles T Spencer, Stephanie B Conant, et al.
Data in Brief|February 7, 2023
Characterization data of reference materials used for phase II of the priority program DFG SPP 2005 "Opus Fluidum Futurum - Rheology of reactive, multiscale, multiphase construction materials"U Pott, C Crasselt, N Fobbe, et al.
Acta Neurochirurgica|July 31, 2020
Surgical management for large vestibular schwannomas: a systematic review, meta-analysis, and consensus statement on behalf of the EANS skull base sectionDaniele Starnoni, Lorenzo Giammattei, Giulia Cossu, et al.
Neuro-Oncology Advances|October 16, 2023
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patientsM J Webb, Bryan J Neth, Lauren M Webb, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|January 25, 2021
Working Toward Consensus on Sporadic Vestibular Schwannoma Care: A Modified Delphi StudyMatthew L Carlson, Michael J Link, Colin L W Driscoll, et al.
Pageof 82